Natural and Synthetic Drugs Approached for the Treatment of Recurrent Aphthous Stomatitis Over the Last Decade
DOI: https://doi.org/10.2147/dddt.s449370
IF: 4.3188
2024-04-23
Drug Design Development and Therapy
Abstract:Cszahreyloren Vitamia, 1, 2 Ghina Nadhifah Iftinan, 3 Irma Rahayu Latarissa, 4 Gofarana Wilar, 4 Arief Cahyanto, 5 Khaled M Elamin, 6 Nasrul Wathoni 1 1 Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia; 2 Departement of Pharmacy, Akademi Farmasi Bumi Siliwangi, Bandung, Indonesia; 3 Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia; 4 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia; 5 Department of Restorative Dentistry, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, Malaysia; 6 Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan Correspondence: Nasrul Wathoni, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Jatinangor, 45363, Indonesia, Tel +622 842 888888 3510, Fax +622 842 888888, Email Recurrent aphthous stomatitis (RAS) refers to a sore and frequently recurring inflammation of the oral tissues, distinguished by the presence of small ulcers that cause significant discomfort and cannot be attributed to any underlying disease. Different treatments have been used for RAS. This review aims to provide a comprehensive overview of the treatment options over the past decade for recurrent aphthous stomatitis (RAS), encompassing both natural and synthetic treatments. It will utilize clinical efficacy studies conducted in vivo and in vitro, along with a focus on the pharmaceutical approach through advancements in drug delivery development. We conducted a thorough literature search from 2013 to 2023 in prominent databases such as PubMed, Scopus, and Cochrane, utilizing appropriate keywords of recurrent aphthous stomatitis, and treatment. A total of 53 clinical trials with 3022 patients were included, with 35 using natural materials in their research and a total of 16 articles discussing RAS treatment using synthetic materials. All the clinical trials showed that natural and synthetic medicines seemed to benefit RAS patients by reducing pain score, ulcer size, and number of ulcers and shortening the healing duration. Keywords: recurrent aphthous stomatitis, drug therapy, natural products, treatment outcome, clinical trial RAS is an oral mucosa disease characterized by recurrent, painful, single or multiple well-demarcated ulcerations with peripheral red halo where healing occurs with or without scarring. 1 In the adult population, 60–85% of patients experience their first ulceration before age thirty. Although the primary causes of RAS remain unknown, certain factors have been identified as triggers for RAS outbreaks, including mental stress, trauma, lack of sleep, iron and folic acid deficiencies, menstruation, anemia, and changes in women's sex hormones. 2,3 With a 39% frequency, children are more likely to experience it. 4 The prevalence rises with the female gender and a higher socioeconomic level and falls with age. 5 Numerous perspectives have proposed that the oral microbiota could be the cause of RAS. Among the possibly significant components of the core microbiota responsible for this condition are Streptococcus, Helicobacter pylori , CMV ( Cytomegalovirus ), and a host of other unknown microorganisms. 6 The presence of ulcers as a significant phenotype in systemic illnesses such as Crohn's disease, Behçet's illness, herpes stomatitis, and ulcerative colitis further compounds the difficulty in determining the etiologic cause. 7 Stress may contribute to the likelihood of developing RAS; hence, it is crucial to address stress management in patients as a means of controlling its recurrence. 8 Numerous therapies for RAS have been studied, such as topical steroids, local anesthetics, topical antibiotics, antiseptics, and analgesic/anti-inflammatory medications. Not every patient will respond well to topical therapies, despite the fact that they can be useful. 9 Several systemic drugs have been investigated to treat RAS, including colchicine, thalidomide, dapsone, and corticosteroid. 10 The current therapeutic options can only lessen the frequency or severity of the lesions. In most cases, the primary goal of RAS treatment is to achieve pain reduction (Visual Analog Scale Score), 11 decrease in ulcer size, decrease in ulcer count, and acceleration of ulcer healing duration. 12 Herbal supplements and natural items have been used for a long time and are recommended as an alternative to systemic pharmaceuticals due to their potent -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal